Head-to-head comparison of 10 natriuretic peptide assays

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 11, 2015, Pages 1825-1837

  Collin Chavagnac, Delphine ^a,b   Dehoux, Monique ^c   Schellenberg, François ^d   Cauliez, Bruno ^e   Maupas Schwalm, Françoise ^f   Lefevre, Guillaume ^g  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b ProBioQual   (France)

^c BICHAT HOSPITAL   (France)

^d SERVICE DE DERMATOLOGIE   (France)

^e HÔPITAL CHARLES NICOLLE   (France)

^f CHU RANGUEIL   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

B type natriuretic peptide; method comparison; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; EDETIC ACID; HEPARIN; NATRIURETIC FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HUMAN; IMMUNOASSAY ANALYZER; INTERMETHOD COMPARISON; MALE; MEASUREMENT ACCURACY; MEASUREMENT PRECISION; NORMAL VALUE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFERENCE VALUE; BLOOD; COMPARATIVE STUDY; HEART FAILURE; IMMUNOASSAY; MIDDLE AGED; REGRESSION ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; REGRESSION ANALYSIS;

EID: 84944111550     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0592     Document Type: Article

References (48)

1. Khan IA, Fink J, Nass C, Chen H, Christenson R, de Filippi CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006;97:1530-4.
2. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006;47:345-53.
3. Rehman SU, Januzzi JL. Natriuretic peptide testing in primary care. Curr Cardiol Rev 2008;4:300-8.
4. Mair J, Gerda F, Renate H, Ulmer H, Andrea G, Pachinger O. Headto-head comparison of B-type natriuretic peptide (BNP) and NTproBNP in daily clinical practice. Int J Cardiol 2008;124:244-6.
5. Giuliani I, Rieunier F, Larue C, Delagneau JF, Granier C, Pau B, et al. Assay for measurement of intact B-type natriuretic peptide prohormone in blood. Clin Chem 2006;52:1054-61.
6. Lam CS, Burnett JC Jr, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007;49:1193-202.
7. Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:355-60.
8. Prontera C, Zucchelli GC, Vittorini S, Storti S, Emdin M, Clerico A. Comparison between analytical performances of polyclonal and monoclonal electrochemiluminescence immunoassays for NTproBNP. Clin Chim Acta 2009;400:70-3.
9. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69.
10. Bruins S, Fokkema MR, Romer JW, DeJongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
11. O'Hanlon R, O'Shea P, Ledwidge M, O'Loughlin C, Lange S, Conlon C, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Cardiac Fail 2007;13:50-5.
12. Rawlins ML, Owen WE, Roberts WL. Performance characteristics of four automated natriuretic peptide assays. Am J Clin Pathol 2005;123:439-45.
13. Di Serio F, Ruggieri V, Varraso L, De Sario R, Mastrorilli A, Pansini N. Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010. Clin Chem Lab Med 2005;43:1263-73.
14. Ordonez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytical considerations. Am J Cardiol 2008;101:9-15.
15. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med 2009;47:762-8.
16. Luckenbill KN, Christenson RH, Jaffe AS, Mair J, Ordonez-Llanos J, Pagani F, et al. Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. Clin Chem 2008;54:619-21.
17. Clerico A, Zaninoto M, Prontera C, Giovannini S, Ndreu R, Franzini M, et al. Study group on Cardiovascular Risk Biomarkers of the Italian Society of Clinical Biochemistry. State of the art of BNP and NT-proBNP immunoassays: the CardioOrmocheck study. Clin Chim Acta 2012;414:112-9.
18. Annales du Contr?le National de Qualité des Analyses de Biologie Médicale: Available from: http://ansm.sante.fr/var/ansm-site/storage/original/application/864745724deb88c48699b2b293ae8fce.pdf.
19. Pereira M, Azevedo A, Severo M, Barros H. Long-term stability of endogenous B-type natriuretic peptide after storage at -20 degrees C or -80 degrees C. Clin Chem Lab Med 2008;46:1171-4.
20. Azzazy HM, Christenson RH, Duh SH. Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems. Clin Chim Acta 2007;384:176-8.
21. Chien TI, Chen HH, Kao JT. Comparison of Abbott AxSym and Roche Elecsys 2010 for measurement of BNP and NT-proBNP. Clin Chim Acta 2006;369:95-9.
22. McBride GB. A proposal of strength of agreement criteria for Lin's concordance correlation coefficient: NINA Client Report 2005; HAM 2005-062.
23. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al; ESC committee for practice guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Eur Heart J 2012;33:1787-847.
24. Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry. Part 1. J Clin Chem Clin Biochem 1983;21:709-20.
25. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.
26. ISO 5725-6. Accuracy (trueness and precision) of measurement methods and results. Part 6: use in practice of accuracy values; 1994.
27. Prontera C, Storti S, Emdin M, Passino C, Zyw L, Zucchelli GC, et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin Chem 2005;51:1274-6.
28. Clerico A, Vittorini S, Passino C. Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance. Clin Chem Lab Med 2011;49:1949-54.
29. Collin-Chavagnac D, Aupetit JF, Barguil Y, Benoit MO, Bricca G, Cauliez B, et al. Inventory of the use of natriuretic peptides in France. Ann Biol Clin 2011;69:653-62.
30. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH. National Academy of Clinical Biochemistry and IFCC committee for standardization of markers of cardiac damage laboratory medicine practice guidelines: analytical issues for biomarkers of heart failure. Clin Biochem 2008;41:222-6.
31. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
32. Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49:1071-8.
33. Seferian KR, Tamm NN, Semenov AG, Mukharyamova KS, Tolstaya AA, Koshkina EV, et al. The brain natriuretic peptide (BNP) precursor is the major immunoreactive form of BNP in patients with heart failure. Clin Chem 2007;53:866-73.
34. Cauliez B, Santos H, Bauer F, Basuyau JP, Nadolny A, Galpy G, et al. Cross-reactivity with endogenous proBNP from heart failure patients for three commercial BNP immunoassays. Clin Chim Acta 2012;413:337-8.
35. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipälä J, Ruskoaho H, Leppäluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of Aand B- type natriuretic peptides. Clin Chem 2004;50:1576-88.
36. Schellenberger U, O'Rear J, Guzzetta A, Jue RA, Protter AA, Pollitt NS. The precursor to B-type natriuretic peptide is an O-linked glycoprotein. Arch Biochem Biophys 2006;451:160-6.
37. Seferian KR, Tamm NN, Semenov AG, Tolstaya AA, Koshkina EV, Krasnoselsky MI, et al. Immunodetection of glycosylated NT-proBNP circulating in human blood. Clin Chem 2008;54:866-73.
38. Nishikimi T, Ikeda M, Takeda Y, Ishimitsu T, Shibasaki I, Fukuda H, et al. The effect of glycosylation on plasma N-terminal proBNP-76 levels in patients with heart or renal failure. Heart 2012;98:152-61.
39. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9.
40. McDonald K, Dahlstrim U, Aspromonte N, Jourdain P, Maisel A, Mueller C, et al. B type-natriuretic peptide: application in the community. Congest Heart Fail 2008;14:12-6.
41. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009;158:422-30.
42. Savarese G, Trimarco B, Dellegrottaglie S, Prastaro M, Gambardella F, Rengo G, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS One 2013;8:e58287.
43. Li P, Luo Y, Chen YM. B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. Heart Lung Circ 2013;22:852-60.
44. Xin W, Lin Z, Mi S. Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev 2015;20:69-80.
45. Richards AM, Troughton RW. Use of natriuretic peptides to guide and monitor heart failure therapy. Clin Chem 2012;58:62-71.
46. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Committee on standardization of markers of cardiac damage of the IFCC. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-93.
47. Franzini M, Masotti S, Prontera C, Ripoli A, Passino C, Giovannini S, et al. Systematic difference between BNP immunoassays: comparison of methods using standard protocols and quality control materials. Clin Chim Acta 2013;424:287-91.
48. Storti S, Prontera C, Emdin M, Passino C, Prati P, Fontani G, et al. Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method. Clin Chem Lab Med 2004;42:1178-85.